---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-084615"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:54:51.788445+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Passage Bio out-licenses three pediatric gene therapy programs to GEMMABio, extends cash runway to Q2 2026

## Summary
- Out-licensed PBGM01, PBKR03, PBML04 to GEMMABio; initial $10M + up to $124M milestones + royalties.
- Cash of ~$91.8M at June 30, 2024; operating runway extended to end of Q2 2026.
- CMO Mark Forman resigned effective Aug 2, 2024; no disagreement with company.
- Appointed Susan Browne as CSO and Stuart Henderson as CBO effective Aug 1, 2024.
- Entered new collaboration with GEMMABio to advance CNS programs including Huntington's disease.

## SEC filing metadata
- accession: 0001104659-24-084615
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000110465924084615/0001104659-24-084615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000110465924084615/tm2420570d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-084615
- JSON: https://secwatch.observer/filing/0001104659-24-084615.json
- Plain text: https://secwatch.observer/filing/0001104659-24-084615.txt

## Key facts
- Executive change
  Mark Forman resigned as Chief Medical Officer at Passage BIO, Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On July 26, 2024, Mark Forman, M.D., Ph.D., notified the Company of his decision to resign from his position as the Company’s Chief Medical Officer, effective as of August 2, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787297/000110465924084615/0001104659-24-084615-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.